TPW
BMRN icon

Transatlantique Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Transatlantique Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,497
Closed -$247K – 215
2025
Q1 		$247K Buy
3,497
+47
+1% +$3.16K 0.1% 196
2024
Q4 		$227K Sell
3,450
-65
-2% -$4.35K 0.09% 193
2024
Q3 		$247K Buy
3,515
+128
+4% +$10.7K 0.09% 197
2024
Q2 		$270K Sell
3,387
-36
-1% -$3K 0.11% 175
2024
Q1 		$299K Sell
3,423
-34
-1% -$3.04K 0.13% 185
2023
Q4 		$333K Sell
3,457
-1,786
-34% -$158K 0.16% 175
2023
Q3 		$464K Sell
5,243
-52
-1% -$4.63K 0.25% 136
2023
Q2 		$459K Buy
5,295
+105
+2% +$9.88K 0.24% 139
2023
Q1 		$505K Buy
5,190
+672
+15% +$69.7K 0.28% 122
2022
Q4 		$466K Sell
4,518
-180
-4% -$16.9K 0.28% 109
2022
Q3 		$399K Buy
4,698
+50
+1% +$4.45K 0.27% 122
2022
Q2 		$385K Buy
+4,648
New +$370K 0.27% 137

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transatlantique Private Wealth's BMRN Position: Q2 2025 in Review

Transatlantique Private Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,497 shares — an estimated $247K sold.

Transatlantique Private Wealth first reported a position in BMRN in Q2 2022 and held it in 12 quarters. The position peaked at $505K in Q1 2023. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Transatlantique Private Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Transatlantique Private Wealth sold 3,497 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $247K.
  • Transatlantique Private Wealth first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 12 quarters.
  • Transatlantique Private Wealth's BioMarin Pharmaceuticals position peaked at $505K in Q1 2023.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Transatlantique Private Wealth's 13F filing for Q2 2025, filed 5 Aug 2025.